DUBLIN--(BUSINESS WIRE)--Research and Markets (http://www.researchandmarkets.com/research/5k7v5z/retinopathy) has announced the addition of the "Retinopathy Partnering 2009-2014" report to their offering.
Retinopathy Partnering 2009-2014 provides understanding and access to the retinopathy partnering deals and agreements entered into by the worlds leading healthcare companies.
The report provides an analysis of retinopathy partnering deals. The majority of deals are discovery or development stage whereby the licensee obtains a right or an option right to license the licensors retinopathy technology. These deals tend to be multicomponent, starting with collaborative R&D, and commercialization of outcomes.
Understanding the flexibility of a prospective partner's negotiated deals terms provides critical insight into the negotiation process in terms of what you can expect to achieve during the negotiation of terms. Whilst many smaller companies will be seeking details of the payments clauses, the devil is in the detail in terms of how payments are triggered - contract documents provide this insight where press releases do not.
This data driven report contains over 20 links to online copies of actual liver disease deals and contract documents as submitted to the Securities Exchange Commission by companies and their partners, where available. Contract documents provide the answers to numerous questions about a prospective partner's flexibility on a wide range of important issues, many of which will have a significant impact on each party's ability to derive value from the deal.
This data driven report includes:
- Trends in retinopathy dealmaking in the biopharma industry since 2009
- Access to summary headline, upfront, milestone and royalty data
- The leading retinopathy deals by value since 2009
In Retinopathy Partnering 2009-2014, the available deals are listed by:
- Headline value
- Upfront payment value
- Royalty rate value
- Company A-Z
- Industry sector
- Stage of development at signing
- Deal component type
- Technology type
- Baxter International
- Biogen Idec
- Boehringer Ingelheim
- Bristol-Myers Squibb
- Daiichi Sankyo
- Dainippon Sumitomo
- Eli Lilly
- Gilead Sciences
- Johnson & Johnson
- Merck & Co
- Mitsubishi Tanabe
- Novo Nordisk
For more information visit http://www.researchandmarkets.com/research/5k7v5z/retinopathy